House votes to bar public funding for ED drugs

The U.S. House of Representatives voted on Friday to bar government insurance programs Medicare and Medicaid from paying for the erectile dysfunction (ED) drugs Viagra, Cialis and Levitra.
Currently, Medicaid spends approximately $15 million a year on ED drugs and the Congressional Budget Office predicts the government would spend $2 billion over 10 years on impotence treatments, once Medicare begins offering prescription drug coverage in 2006.
The bill must still pass in the Senate where a similar measure has also been introduced.
The pharmaceutical industry said it would work to keep the bill out of the Senate.
"Unfortunately, the House is telling these men (anti-impotence drug patients), 'Tough luck, you are on your own,' Ken Johnson, senior vice president of the Pharmaceutical Research and Manufacturers of America (PhRMA) told The New York Times. "Hopefully, the Senate will view this important health issue with a little more compassion."
In passing the bill, 100 Democrats joined with 185 Republicans to approve the measure by a final vote of 285 to 121.
The measure is part of an overall spending bill providing more than $600 billion for a wide array of health and education programs including money for the National Institutes of Health, student loans and programs to fight AIDS.

 

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Who Needs a Gold Watch, Anyway?

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.